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line) infection, arrhythmias and pump thrombosis [4]. The 
incidence of pump thrombosis was reported in a range of 
1.4–4 % in 2010 [5]. We report a case of early postoperative 
pump thrombosis.
A 46-year-old man with dilated cardiomyopathy and 
end-stage heart failure, despite optimal medical and 
implantable cardioverter defibrillator therapy, was accepted 
on the Eurotransplant waiting list for heart transplant on 
May 2013. In July 2013, due to clinical deterioration, he 
received—in a non-emergency setting—an LVAD type 
HeartMate II (Thoratec Corp. Pleasanton CA, USA) as a 
bridge to transplantation [Fig. 1, label 1]. Postoperative 
recovery was without complications, and the patient was 
discharged to a cardiac rehabilitation centre 19 days after 
insertion of the device. In all, 27 days after implantation, 
the level of lactate dehydrogenase (LDH) increased from 
254 U/l (pre-VAD) to 704 and 1050 U/l [Fig. 1, label 2]. 
This raised the suspicion of pump thrombosis and low-
molecular-weight heparin was added to International Nor-
malized Ratio (INR)-guided (1.5–2.5) acenocoumarol and 
100 mg of aspirin daily. However, the LDH levels further 
increased to 2801 U/l [Fig. 1, label 3]. The patient was hos-
pitalised. Although computed tomography (CT) using con-
trast showed no signs of obstruction in the VAD circuit and 
LVAD power requirement did not increase [Fig. 1, label 
3], unfractionated heparin (target Activated Partial Thro-
moplastin Time (APTT) level 40–60 s) was given intra-
venously. This led to a drop in the LDH level to 778 U/l 
[Fig. 1, label 4]. The patient was discharged, but within a 
few days he complained of fatigue, dyspnoea and reduced 
exercise tolerance. On re-admission, echocardiography 
showed an aortic valve opening at each contraction, which 
was observed more often than in previous echocardiogra-
phies. There were no signs of aortic valve regurgitation. 
Right ventricular function was impaired, indicated by a tri-
Abstract The clinical course of a patient with a left ven-
tricular assist device is described. A total of 6 weeks after 
device insertion, the lactate dehydrogenase (LDH) level in-
creased to 2801 U/l despite adding low-molecular-weight 
heparin to acenocoumarol and aspirin. Pump thrombosis 
was suspected but unconfirmed by computed tomography. 
Increased pump power requirement did not occur. Insti-
tuting unfractionated heparin caused a drop in the LDH 
level. After discontinuing heparin, the LDH levels rose to 
5529 U/l whereupon pump replacement was performed. 
LDH levels, combined with clinical deterioration and 
right heart catheterisation, led to the diagnosis of pump 
thrombosis.
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Introduction
Implantation of a permanent left ventricular assist device 
(LVAD) in a patient with cardiogenic shock must be avoided. 
Short-term external left ventricular support and appropriate 
pharmacological treatment can be a feasible alternative [1, 
2]. Mechanical circulatory support by an implantable device 
is, however, the current therapy of choice for patients who 
deteriorate clinically while on the waiting list for a heart 
transplant [3]. Well-known complications after insertion of 
an LVAD are bleeding, right ventricular dysfunction, (drive-
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cuspid annulus plane systolic excursion of 10 mm. A veloc-
ity of the tricuspid annular systolic motion s’RV of 5.3 cm/s 
was more impaired than earlier. Pump power requirement 
remained unaltered. The LDH level rose to 1967 U/l [Fig. 1, 
label 5]. No lung embolisms or LVAD obstructions were 
found by repeated contrast CT. Right heart catheterisation 
showed a cardiac output of 2.96 l/min, which was less than 
the pre-LVAD calculation of 4.45 l/min. Besides our sus-
picion of LVAD thrombosis, we ruled out right ventricular 
overload by reducing pump speed with 400 rotations/min. 
Sildenafil and milrinone were added to the medication in 
an attempt to improve right ventricular function but did 
not lead to clinical or biochemical improvement. In con-
trast, LDH rose to 5529 U/l [Fig. 1, label 6]. Since we had 
no other possible explanation than pump thrombosis, we 
replaced the LVAD next day using the subcostal approach 
and found a thrombus localised on the bearing of the inlet 
cannula (Fig. 2). Clopidogrel replaced aspirin, and the tar-
get INR level was raised to 2.5–3.5 by means of home mon-
itoring. The patient recovered and was discharged first to 
the cardiac rehabilitation centre and then home. Currently 
(28 April 2014) the LDH level is 404 U/l.
Discussion
Our patient demonstrates that the diagnosis of LVAD throm-
bus can be difficult because of discrepancies in biochemical, 
echocardiographic and LVAD diagnostics. First, the initially 
raised LDH concentrations could have also been a marker 
of haemolysis instead of thrombosis since the haemoglo-
bin decreased from 7.7 to 4.4 mmol/l. Second, the pump 
power requirement was more or less constant in the interval 
between LVAD insertion and exchange. Third, subsequent 
echocardiography (eight recordings between first LVAD 
and the replacement) revealed stable findings. In particular, 
the frequency of aortic valve opening did not increase dur-
ing follow-up, except directly before LVAD replacement. 
Finally, repeated contrast CTs did not support our clinical- 
and biochemical-based suspicion of LVAD thrombosis.
Increased power requirement of the pump can be pathog-
nomonic for an impeller thrombus but is absent when a 
thrombus is localised at a HeartMate II inlet bearing ball 
[6]. We did not apply the suggested ramp test [7]. An unex-
pected, abrupt increase in incidence of LVAD thrombosis 
was reported recently [8]. In 2011, the incidence of con-
Fig. 2 Thrombus localised on the bearing of the inlet cannula
 
Fig. 1 Lactate dehydrogenase 
(LDH) level (primary Y axis), 
haemoglobin (secondary Y axis) 
and left ventricular assist device 
pump power (secondary Y axis) 
during follow-up. Numbers 1–6 
(top of figure) correspond with 
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firmed pump thrombosis was 2.2 %. By January 2013, this 
had increased to 8.4 % (95 % confidence interval 5–13.9). In 
addition, the median time from implantation to thrombosis 
was 18.6 months, but is now much shorter, i.e. 2.7 months. 
Six weeks after device insertion, a sharp rise in LDH level 
closely suggested confirmed pump thrombosis. The exact 
cause of the increased rate of thrombosis remains unclear. 
After confirmation of the diagnosis, thrombolytic therapy 
might be an option [9] but pump replacement can be per-
formed with low mortality [10]. It is crucial to monitor LDH 
levels, among other parameters, to track pump thrombosis 
in time [11] and apply the algorithm for the diagnosis and 
management of suspected pump thrombus [12].
In summary: in a LVAD patient receiving adequate oral 
anticoagulation and antiplatelet therapy despite no increase 
in pump power requirement, in the case of LDH increase 
and decrease after intravenous anticoagulation, the diagno-
sis of pump thrombosis located at the inlet bearing ball is 
highly likely. Consequently, only pump exchange is prob-
ably life-saving.
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